Avadel Pharmaceuticals PLC (AVDL)vsZoetis Inc (ZTS)
AVDL
Avadel Pharmaceuticals PLC
$21.64
0.00%
HEALTHCARE · Cap: $2.12B
ZTS
Zoetis Inc
$82.83
-5.13%
HEALTHCARE · Cap: $36.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 3709% more annual revenue ($9.47B vs $248.52M). ZTS leads profitability with a 28.2% profit margin vs -0.0%. AVDL appears more attractively valued with a PEG of 0.07. ZTS earns a higher WallStSmart Score of 64/100 (C+).
AVDL
Hold41
out of 100
Grade: D
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.6%
Fair Value
$73.50
Current Price
$21.64
$51.86 discount
Margin of Safety
+19.4%
Fair Value
$159.74
Current Price
$82.83
$76.91 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.5% revenue growth
0.0% earnings growth
Operating margin of 0.0%
Weak financial health signals
Expensive relative to growth rate
Trading at 10.6x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AVDL
The strongest argument for AVDL centers on PEG Ratio. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : AVDL
The primary concerns for AVDL are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
AVDL profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
AVDL carries more volatility with a beta of 1.63 — expect wider price swings.
ZTS is growing revenue faster at 3.0% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 41/100), backed by strong 28.2% margins. AVDL offers better value entry with a 70.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avadel Pharmaceuticals PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?